News

Article

NeurologyLive® Friday 5 — September 20, 2024

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 20, 2024.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Important Changes Are Coming to Medicare in 2025: What You Need to Know to Help Your Patients

In our latest blog post from the National MS Society (Society), Nicole M. Boschi, PhD, the director of regulatory affairs at the Society, talked about the impact of the upcoming Medicare Part D and Medicare Advantage changes for the multiple sclerosis community.

Important Changes Are Coming to Medicare in 2025: What You Need to Know to Help Your Patients

2: Apple's Latest Health Updates: A Neurological Game-Changer in Disguise

In our latest guest article from Neal K. Shah, the chief executive officer of CareYaya Health Technologies, he discussed how Apple's new health features could potentially be a game-changer for neurological health.

Apple's Latest Health Updates: A Neurological Game-Changer in Disguise

3: 2024 Revisions to McDonald Diagnostic Criteria for Multiple Sclerosis: Peter Calabresi, MD

The codirector of the Precision Medicine MS Center at Johns Hopkins University discussed the new updates to the MS diagnostic criteria presented at the 40th ECTRIMS Congress in Copenhagen. [WATCH TIME: 5 minutes]

2024 Revisions to McDonald Diagnostic Criteria for Multiple Sclerosis: Peter Calabresi, MD

4: NeuroVoices: Antonio Scalfari, MD, PhD, on a Broader Perspective of Understanding Smoldering Disease in Multiple Sclerosis Progression

In our latest Q&A for NeuroVoices, the consultant neurologist at Imperial College Healthcare Trust discussed a proposed concept of smoldering disease in multiple sclerosis that covers progressive symptoms that go beyond traditional focal inflammatory activity.

NeuroVoices: Antonio Scalfari, MD, PhD, on a Broader Perspective of Understanding Smoldering Disease in Multiple Sclerosis Progression

5: Mind Moments: Therapeutic Updates and Progress in Treating Becker Muscular Dystrophy

In our newest podcast episode, Joanne Donovan, MD, PhD, chief medical officer at Edgewise Therapeutics, sat down to discuss the clinical program of EDG-5506, an investigational drug in development for Becker muscular dystrophy, and the recent progress in treating and understanding Becker muscular dystrophy.

 Episode 124: Therapeutic Updates and Progress in Treating Becker Muscular Dystrophy
Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
 Xavier Montalban, MD, PhD
Marcello Moccia, MD, PhD
Mikael Cohen, MD
Robert J. Fox, MD; Andreas Muehler, MD, MBA
© 2024 MJH Life Sciences

All rights reserved.